Literature DB >> 1380531

Superantigen-mediated human monocyte-T lymphocyte interactions are associated with an MHC class II-, TCR/CD3-, and CD4-dependent mobilization of calcium in monocytes.

B Damaj1, W Mourad, P H Naccache.   

Abstract

The present study was designed to examine the potential involvement of calcium ions as second messengers in the mediation of the staphylococcal enterotoxin A (SEA)/MHC class II-induced activation of human monocytes. Treatment of monocytes with a monomeric form of SEA failed to induce detectable changes in the level of intracellular calcium in either monocytes or THP-1 cells. However, cross-linking of SEA with biotin-avidin induced a rapid and transient increase in calcium levels in monocytes and in INF-gamma-treated THP-1 cells. This artificial cross-linking system was reproduced by natural physiologic ligands expressed on the surface of T lymphocytes. Delayed, transient, and concentration (cell as well as toxin)-dependent increases in the cytoplasmic level of free calcium in SEA-treated monocytes were observed upon the addition of autologous resting T cells or purified CD4+ cells, but not of CD8+ cells, B cells, or neutrophils. Antibodies against MHC class II Ag, TCR/CD3, and CD4 molecules inhibited the SEA-dependent interaction between monocytes and T cells as indicated by significant decreases in the rise of calcium levels observed in monocytes. Anti-CD8 and anti-class I antibodies did not affect the interaction between the monocytes and the T cells and failed to alter the calcium response. Taken together, these results suggest that the SEA-induced, T cell-dependent calcium mobilization in monocytes requires physical interactions between SEA-MHC class II, TCR/CD3, and CD4 molecules. The ability to mediate a T cell-dependent calcium increase in monocytes was shared by several enterotoxins including staphylococcal enterotoxin B and toxic shock syndrome toxin-1. The characteristics of the SEA-mediated calcium mobilization in monocytes strongly support the hypothesis that this response is an integral part of the signal transducing machinery linked to MHC class II molecules.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380531

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Mapping of staphylococcal enterotoxin A functional binding sites and presentation by monoclonal antibodies and fusion proteins.

Authors:  W Mahana
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Localization of binding sites of staphylococcal enterotoxin B (SEB), a superantigen, for HLA-DR by inhibition with synthetic peptides of SEB.

Authors:  J L Komisar; S Small-Harris; J Tseng
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

3.  Langerhans' cell depletion by staphylococcal superantigens.

Authors:  S Pickard; G Shankar; K Burnham
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

4.  Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production.

Authors:  T Darville; L B Milligan; K K Laffoon
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.

Authors:  Julie M Decker; Kenneth P Zammit; Juliet L Easlick; Mario L Santiago; Denise Bonenberger; Beatrice H Hahn; Olaf Kutsch; Frederic Bibollet-Ruche
Journal:  Virology       Date:  2009-09-12       Impact factor: 3.616

6.  A natural mutation of the amino acid residue at position 60 destroys staphylococcal enterotoxin A murine T-cell mitogenicity.

Authors:  W Mahana; R al-Daccak; C Lévéillé; J P Valet; J Hébert; M Ouellette; W Mourad
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  T-cell activation or tolerization: the Yin and Yang of bacterial superantigens.

Authors:  Aline Sähr; Sandra Förmer; Dagmar Hildebrand; Klaus Heeg
Journal:  Front Microbiol       Date:  2015-10-20       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.